Agenus Inc. and Noetik have announced a new collaboration to develop AI-enabled predictive biomarkers for the immuno-oncology combination of botensilimab and balstilimab. This partnership aims to accelerate precision immunotherapy by leveraging Noetik's virtual cell models and extensive tumor data. The collaboration builds on a 2024 Cancer Discovery study highlighting botensilimab's unique immune activation mechanisms. By integrating AI technologies with clinical data, the initiative seeks to identify predictive biomarkers, improve trial success, and enhance patient outcomes, aligning with national priorities for personalized cancer treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。